Publication | Open Access

Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis

Bone DiseaseSkeletal TraumaBone HealthPharmacotherapySafety AnalysisMedicineMandatory Bone-protecting AgentsOsteoporosisOrthopaedic SurgeryFracture RateSpinal Fracture